Investigators evaluated long-term outcomes among individuals who have eosinophilic esophagitis (EoE) and initiated first-line treatment with a food elimination diet after experiencing remission ...
Mirna Chehade, MD, MPH, discusses the challenges faced by patients with eosinophilic esophagitis (EoE), including the absence of predictive factors for personalized treatment, the social implications ...
SAN FRANCISCO & FORT WORTH, Texas--(BUSINESS WIRE)--TPG Capital, the private equity platform of alternative asset firm TPG, announced today that it has formed a new specialty pharmaceutical company ...
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for ...
If you have a new diagnosis of eosinophilic esophagitis (EoE), you’ll want to know what the best treatment is for you. The mainstays of treatment for EoE are proton pump inhibitors, steroids, diet ...
The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed the safety and efficacy of the drug, which ...
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for which ...
VICTORIA, BC, Feb. 25, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company specializing in precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results